Northern Trust Corp Acquires 74,836 Shares of Enovis Co. (NYSE:ENOV)

Northern Trust Corp grew its position in Enovis Co. (NYSE:ENOV - Free Report) by 15.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 547,686 shares of the company's stock after purchasing an additional 74,836 shares during the period. Northern Trust Corp owned approximately 0.96% of Enovis worth $24,032,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. UMB Bank n.a. increased its position in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after acquiring an additional 437 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its position in shares of Enovis by 19.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company's stock valued at $677,000 after acquiring an additional 2,518 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Enovis in the fourth quarter valued at about $437,000. Tributary Capital Management LLC increased its position in shares of Enovis by 33.9% in the fourth quarter. Tributary Capital Management LLC now owns 566,089 shares of the company's stock valued at $24,840,000 after acquiring an additional 143,258 shares during the last quarter. Finally, Park Avenue Securities LLC increased its position in shares of Enovis by 12.5% in the fourth quarter. Park Avenue Securities LLC now owns 11,988 shares of the company's stock valued at $526,000 after acquiring an additional 1,333 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Price Performance

Shares of ENOV stock traded up $0.37 during trading on Friday, hitting $36.10. The company had a trading volume of 539,929 shares, compared to its average volume of 780,866. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The firm has a market capitalization of $2.06 billion, a P/E ratio of -16.49 and a beta of 1.79. The stock's 50-day moving average price is $35.15 and its 200 day moving average price is $41.42. Enovis Co. has a one year low of $29.32 and a one year high of $52.76.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.07. The business had revenue of $558.83 million during the quarter, compared to analysts' expectations of $558.80 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.50 earnings per share. Equities analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ENOV shares. JMP Securities lowered their price target on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Canaccord Genuity Group decreased their target price on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Wednesday. Finally, Needham & Company LLC decreased their target price on Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $58.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.